SpringWorks Therapeutics (SWTX) Plunges 3.46% Amid Four-Day Decline

Generado por agente de IAAinvest Movers Radar
martes, 8 de abril de 2025, 8:07 pm ET1 min de lectura

SpringWorks Therapeutics (SWTX) shares fell 3.46% today, marking the fourth consecutive day of decline, with a total drop of 23.24% over the past four days. The stock price hit its lowest level since January 2025, experiencing an intraday decline of 5.19%.

Finepoint Capital LP increased its stake in

by 15.0% during the fourth quarter, indicating a bullish outlook on the company's future prospects. This move by a significant investor suggests confidence in the company's growth potential and could influence other investors' decisions.

Evercore ISI raised their target price on

Therapeutics shares from $60.00 to $65.00, with analyst Cory Kasimov maintaining a buy rating. This adjustment reflects a positive outlook on the company's performance and potential for future growth, which could attract more investors and drive up the stock price.

BofA Securities analyst Alec Stranahan also maintains a buy rating for SpringWorks Therapeutics, keeping the target price at $55. This consistent positive rating from a reputable analyst further supports the bullish sentiment surrounding the company, potentially influencing investor confidence and stock performance.

author avatar
Ainvest Movers Radar

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios